About this Research Topic
Pirfenidone is a drug approved for idiopathic pulmonary fibrosis, a severe form of idiopathic interstitial pneumonias. Pirfenidone is a small synthetic molecule with high oral bioavailability, exerting an antifibrotic activity, but also anti-oxidant and anti-inflammatory effects. These effects have been attributed to the inhibition of several growth factors (in particular transforming growth factor-β, but also platelet-derived growth factor and beta fibroblast growth factor), matrix metalloproteinases, and pro-inflammatory mediators (such as interleukin-1β and tumour necrosis factor-α), and possibly also an improvement of mitochondrial function and modulation of lymphocyte activation. Given the activation of similar profibrotic pathways in lung and heart disease, the crucial role of fibrosis in several cardiac disorders, and the wide spectrum of activity of pirfenidone, this drug has been evaluated with interest as a potential treatment for cardiac disorders. In animal studies, pirfenidone has shown cardioprotective effects across different species and in a variety of models of cardiomyopathy.
This special issue aims to provide an overview of the issues related to pirfenidone as a potential cardioprotective strategy.
The topic is looking to cover the following themes.
- Cardiac protection by pirfenidone: possible mechanisms.
- Pirfenidone after myocardial infarction.
- Pirfenidone in other disease settings (pressure overload, atrial fibrillation...).
- Rationale for pirfenidone therapy in heart failure with preserved ejection fraction.
We welcome all types of manuscripts, including original basic science reports, review articles, methodology papers, translational research, and clinical studies.
Keywords: Pirfenidone, fibrosis, cardiac protection, myocardial infarction, HFpEF, Heart failure with preserved ejection fraction
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.